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IntroDuctIon
Adult bile ducts consist of highly functional biliary epithelial 
cells1, which regulate bile homeostasis and modulate inflamma-
tory responses. These cells are also known as cholangiocytes and 
represent the main cell type affected in cholangiopathies2,3—a 
diverse group of liver disorders including diseases such as primary 
biliary cirrhosis and primary sclerosing cholangitis. Despite the 
growing importance of these diseases, research in biliary physiol-
ogy and the development of new therapeutics has been hampered 
by the lack of robust platforms for disease modeling and high-
throughput drug screening3. Although animal models exist, their 
capacity for fully reproducing human pathophysiology is lim-
ited4,5, and access to primary biliary tissue remains problematic, 
prohibiting large-scale experiments. Here, we describe a protocol 
for the generation of large quantities of CLCs from human hPSCs, 
which can be applied to model cholangiopathies in vitro and to 
validate the effects of therapeutic compounds6.
Development of the protocol
The protocol for the generation of CLCs6 was developed by reca-
pitulating key stages of native bile duct development (Fig. 1a). 
Cholangiocytes originate from HBs, a bipotent population 
of embryonic liver progenitor cells7 that can also differentiate 
into hepatocytes. Hepatoblasts surrounding the portal vein give 
rise to a monolayer of immature cholangiocyte progenitor cells 
(the ductal plate)7, which undergoes a process of 3D remodeling 
and maturation, resulting in functional bile ducts.
The generation of bipotent HBs was based on our established 
methodology for producing hPSC-derived hepatocyte-like cells8. 
To achieve biliary commitment of HBs, we used physiological 
cues reported to control biliary specification, such as activin A 
(a member of the TGF-β superfamily)7,9 and fibroblast growth 
factor (FGF) 10 (ref. 10). Screening a variety of growth factors, 
we also identified a requirement for retinoic acid6. The combined 
activation of these signaling pathways was sufficient to promote 
differentiation of HBs into CPs expressing early biliary markers, 
including KRT19 and SOX9 (ref. 6).
Maturation of native cholangiocytes happens in synchrony with 
3D re-arrangement of the ductal plate into tubular structures7. Most 
of the functional properties of the biliary epithelium are associated 
with absorption and secretion processes, which require a polarized 
epithelium forming a lumen and therefore cannot be accurately 
reproduced by cells organized in monolayer11,12. Consequently, for 
the final stage of our protocol promoting CP maturation to CLCs, 
we developed a 3D culture system based on previous studies using 
Matrigel and epidermal growth factor (EGF)13,14 that promotes 
spontaneous differentiation of HBs into cystic structures express-
ing early biliary markers such as KRT19 (refs. 13,14). Prolonged 
culture of CPs under these conditions resulted in CLC organoids 
with a central lumen demonstrating characteristic functional prop-
erties such as γ-glutamyl transferase (GGT) activity6.
Applications
The mechanisms controlling development of the human biliary 
tree remain poorly understood. Indeed, developmental studies 
in humans are limited by minimal access to fetal tissue, whereas 
animal models fail to fully recapitulate the development of the 
human biliary tree or the phenotype of developmental disorders5. 
Our in vitro system could address some of these challenges, as it 
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the difficulty in isolating and propagating functional primary cholangiocytes is a major limitation in the study of biliary disorders 
and the testing of novel therapeutic agents. to overcome this problem, we have developed a platform for the differentiation of 
human pluripotent stem cells (hpscs) into functional cholangiocyte-like cells (clcs). We have previously reported that our 26-d  
protocol closely recapitulates key stages of biliary development, starting with the differentiation of hpscs into endoderm and 
subsequently into foregut progenitor (Fp) cells, followed by the generation of hepatoblasts (HBs), cholangiocyte progenitors (cps) 
expressing early biliary markers and mature clcs displaying cholangiocyte functionality. compared with alternative protocols 
for biliary differentiation of hpscs, our system does not require coculture with other cell types and relies on chemically defined 
conditions up to and including the generation of cps. a complex extracellular matrix is used for the maturation of clcs; therefore, 
experience in hpsc culture and 3D organoid systems may be necessary for optimal results. Finally, the capacity of our platform 
for generating large amounts of disease-specific functional cholangiocytes will have broad applications for cholangiopathies, in 
disease modeling and for screening of therapeutic compounds. 
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relies on a stepwise differentiation protocol that closely mimics 
embryonic bile duct development. Therefore, substantial numbers 
of cells corresponding to different embryological stages can be 
easily generated, enabling mechanistic large-scale studies in biliary 
specification or developmental disorders. Accordingly, we applied 
this methodology to interrogate the role of TGF-β and Notch 
signaling in biliary tubulogenesis, and reproduce the Alagille syn-
drome phenotype in vitro6. The same principle could be used in 
future studies to explore a broad spectrum of pathways that could 
be involved in bile duct development and pathogenesis.
CLCs also recapitulate many physiological functions of cholan-
giocytes in vitro, as well as their defects in the context of disease 
when using hPSCs derived from patients with cholangiopa-
thies6. Consequently, CLCs could present an optimal platform 
for modeling biliary disease, validating therapeutic compounds 
and screening for novel treatment agents. We have already dem-
onstrated proof of principle for the feasibility of this application 
by reproducing the effects of the drugs verapamil and octreotide 
in our culture system6 and using patient-specific hiPSCs to iden-
tify a new application for the experimental compound VX809 in 
the management of cystic fibrosis cholangiopathy6. Importantly, 
the capacity of our system for generating substantial numbers of 
CLCs6, combined with its compatibility with large-scale experi-
mental formats (24- and 48-well plates)6, could set the foundation 
for the use of patient-derived CLCs to develop high-throughput 
drug screening platforms for cholangiopathies in the future.
Comparison with other methods
Primary cholangiocyte isolation has been reported15–17. However, 
such methodologies are technically challenging, support only 
short-term growth with limited expansion and generate limited 
numbers of cells, all of which are not compatible with large-scale 
experiments15–17. Furthermore, primary cholangiocytes cultured 
in monolayer systems have not been shown to maintain their 
functional properties15–17.
Two other protocols have been described for generating biliary 
epithelium from hPSCs18,19. The method by Dianat et al. results in 
cells with a transcriptional signature6,19 compatible with a subpop-
ulation of cholangiocytes located in the canals of Hering, known as 
small cholangiocytes20. Therefore, this approach is optimized for 
studies on small cholangiocytes and complements our protocol, 
which is aimed toward the production of large cholangiocytes. 
The method by Ogawa et al. generates cholangiocyte organoids 
expressing mature markers and demonstrating biliary functional-
ity; however, biliary specification is based on a coculture system 
with mouse OP9 cells12. Although a mixed culture system may 
recapitulate more closely the native niche of HBs/cholangiocytes, 
it is technically more challenging and presents several limitations. 
Indeed, OP9 cells are derived from bone marrow and are known 
to promote hematopoietic differentiation of ESCs by secreting 
factors such as macrophage colony-stimulating factor (M-CSF). 
This poses substantial limitations for mechanistic studies in biliary 
specification and early biliary development, as unknown secreted 
factors could interfere with experimental outcomes. Furthermore, 
the heterogeneity of the cell population in a coculture system 
renders –omics studies, such as genome-wide analyses, more chal-
lenging. Consequently, the platform by Ogawa et al. may be better 
suited for studies in which accurate reproduction of a complex 
cellular niche is critical, whereas our system is more optimized for 
mechanistic studies in biliary development and therapeutics.
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Figure 1 | Generation of cholangiocyte-like cells (CLCs) from human pluripotent stem cells (hPSCs). (a) Schematic representation of the protocol for the 
generation of hPSC-derived CLCs. Ly294002 is a phosphatidylinositol-3-OH kinase inhibitor. Image adapted with permission from ref. 6, Nature Publishing 
Group. The procedure steps corresponding to each stage are noted for reference. (b) Light microscopy images of cells at key stages of CLC differentiation.  
The procedure steps and day numbers corresponding to each image are noted for reference. Scale bars for hPSCs, DE, FPs, CPs, CLCs: 500 µm; HBs: 100 µm; 
zoomed-in images: 50 µm. BMP, bone morphogenetic protein; CDM, chemically defined medium; CP, cholangiocyte progenitor; DE, definitive endoderm;  
EGF, epidermal growth factor; FGF, fibroblast growth factor; FP, foregut progenitor; HB, hepatoblast; HGF, hepatocyte growth factor; RA, retinoic acid;  
RPMI, Roswell Park Memorial Institute medium; SB, SB-431542; William’s E, William’s E Medium.
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Limitations
There are two main limitations to our platform. Our system relies 
on a complex extracellular matrix (Matrigel). The composition of 
Matrigel is not fully defined, and variation in the growth factor 
and protein contents of each batch could affect the efficiency of 
the final stage of our protocol. Furthermore, the use of Matrigel 
could render the translation of our platform to good manu-
facturing practice conditions challenging and prevent in vivo  
applications toward cell-based therapy and regenerative medicine. 
Another important consideration is the maturity of the gener-
ated cells. CLC organoids express both early and mature biliary 
markers and maintain some fetal characteristics corresponding 
more accurately to a stage between fetal and fully mature bile 
ducts. Consequently, before modeling adult biliary disorders, 
CLCs should be tested for the presence of the relevant mature 
markers and functionality.
Experimental design
Our method describes the generation of hPSC-derived CLC orga-
noids over a period of 26 d. Biliary differentiation is achieved 
through five key stages of recapitulating bile duct development 
(Fig. 1). Our protocol starts with the plating of hPSCs on day 
0 (d0), and we refer to the first day of differentiation as day 1. 
The first stage (days 1–3) results in the generation of definitive 
endoderm (DE) cells. These cells correspond to the common pro-
genitor from which the liver, lung, pancreas, alimentary tract and 
thyroid arise. Subsequently, DE cells are differentiated into FP 
cells (stage 2, days 4–8), which correspond to precursors of the 
liver, pancreas, lung and thyroid lineages found in the anterior 
portion of the embryonic alimentary canal. In the third stage 
(days 9–12), FP cells are differentiated into HBs, bipotent pro-
genitors of hepatocytes and cholangiocytes, which can give rise 
to both. The fourth stage (days 13–16) results in biliary commit-
ment of HBs and the generation of CPs, which represent early 
cholangiocytes forming the ductal plate in vivo. In the final stage 
of our method (days 17–26), CPs form functional CLC organoids 
in 3D culture conditions.
Starting population considerations. We have demonstrated 
that this protocol is reproducible with four different hPSC lines6 
and embryonic stem (ES) cells (Fig. 2). Variability in differen-
tiation capacity is a common issue with hPSC lines, which may 
reflect the efficiency and timing of our protocol. Therefore, some 
minor optimization steps may be required for each hPSC line, as 
described in the following sections.
Preparation of hPSCs. To achieve high differentiation efficiency, 
the generation of a near-homogeneous DE population is critical. 
For that, hPSCs must exhibit optimal morphology and minimal 
background differentiation. They should first be allowed to grow 
to near confluence (70–80%), and then they should be broken 
into small clumps and plated at high density, as described in the 
sections below (Fig. 1b; Steps 1–9). Clump size and density have 
a critical role in this step. Very small clumps or single cells are not 
viable after the first day of differentiation, whereas large clumps 
differentiate only partially, maintaining the expression of pluripo-
tency markers at their center. Low densities prevent the cells from 
reaching near confluence by the end of the first stage. This can 
have a negative impact on paracrine signaling, cell migration and 
cell-to-cell contact, which are critical factors for efficient forma-
tion of the foregut epithelium. A minimum of 24 h should be 
allowed for the hPSCs to adhere to the plate before starting dif-
ferentiation; however, this period can be extended to a maximum 
of 48 h if the clump size is thought to be too small.
Generation of DE and FP. Definitive endoderm differentiation is 
characterized by morphological changes, epithelial–mesenchymal 
transition (Fig. 1b), substantial proliferation of the cells and 
increased death of cells that fail to differentiate. By the end of d3, 
the cells should be approaching confluence (Fig. 1b) and express-
ing Sox17 and EOMES homogeneously (>90%, Figs. 3 and 4). 
Cell proliferation continues during the FP stage, and by the end 
of d8 the cells should be forming a confluent epithelium with 
cells exhibiting a characteristic rhomboidal morphology (Fig. 1b). 
The generation of a near-homogeneous population of FP cells is 
critical for the efficiency of later stages. Therefore, we recommend 
that differentiations be optimized to generate cell populations 
with >95% purity for endoderm and foregut markers (Figs. 3 
and 4) such as GATA4 and FOXA2. In particular, for resistant 
hPSC lines with substantial contamination from partially dif-
ferentiated cells, we recommend splitting the cells at the foregut 
stage (day 6). For lines with lower proliferation rates and good 
differentiation efficiency, this step is optional. If the cells are split 
at this stage, it is very important that they be dissociated to single 
cells and replated at a density allowing the formation of a fully 
confluent epithelium by day 8.
Generation of bipotent HBs. Cell proliferation begins to reduce 
at this stage, although cells should continue to proliferate at a 
lower rate. We have noticed variability in the proliferation rates of 
different hPSC lines. Differentiation of FP to HBs should result in 
a near-homogeneous population (>95%) expressing hepatoblast 
markers (CK19, AFP) (Figs. 3 and 4), which is important for the 
efficiency of subsequent steps. A high cell density of FPs forming 
a monolayer of relatively small cells is critical to the success of this 
stage. For resistant hPSC lines, this stage could be prolonged by 
24 h to improve differentiation efficiency. However, substantial 
prolongation of HB differentiation carries the risk of committing 
a large proportion of cells to the hepatic lineage, which results in 
increased hepatoblast/hepatocyte contamination at the next stage 
and reduced biliary lineage commitment.
Generation of CPs. Cell proliferation should increase compared 
with the previous stage, and by the fourth day of cholangiocyte 
progenitor differentiation substantial overgrowth should be 
seen (100% confluence and/or areas of cells forming multiple 
layers). Differentiation of HBs to CPs is heterogeneous, resulting 
CK
7/
CK
19
/D
AP
I
Figure 2 | Derivation of CLCs from embryonic stem (ES) cells. IF analyses 
demonstrating the expression of key biliary markers (CK7 (green), CK19 
(red)) in a CLC organoid generated from ES cells (H9). Scale bars, 100 µm. 
See table 1 for a detailed list of the antibodies and concentrations used.
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in a mixed population of CPs (75%), HBs (15%) and cells at 
intermediate stages (Fig. 4). Consequently, although hepatic 
markers such as AFP can still be detected, early biliary mark-
ers such as CK19 and SOX9 should also be expressed almost 
homogeneously (Figs. 2 and 3). Poor efficiency at this stage 
(<75% SOX9+ cells) could result in incomplete maturation of 
CLC organoids in the next step. The quality and duration of the 
HB stage is critical to limiting HB contamination and ensuring 
biliary commitment.
Therefore, for resistant hPSC lines, we recommend optimizing 
the duration and efficiency of HB differentiation as described 
in the previous section (Generation of bipotent HBs) and in the 
Troubleshooting section.
Generation of CLC organoids. For the final stage of our protocol, 
CPs are dissociated into small clumps and transferred to 3D culture 
conditions. Density and clump size are the factors most critical to 
the success of this step. Very high densities do not allow adequate 
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Figure 4 | Flow cytometry analyses demonstrating the expression of characteristic markers at key stages of CLC differentiation. CLC organoids were harvested 
as described in Procedure Steps 40–47. Cells were dissociated into single cells following incubation with TrypLE for 5 min at 37 °C and fixed with 4% (wt/vol) 
PFA for 20 min at 4 °C. The cells were stained for IF as previously described6, using the antibodies provided in table 1. A standard gating strategy was 
used22 (demonstrated in supplementary Fig. 2). A minimum of 2 × 104 gated events were used for analysis. Postsort fractions are indicated in the quadrants 
of each graph. The average efficiency of differentiation from hPSCs to CLCs across three lines (CK7+/Sox9+ organoids) was 77% (s.d. = 6.5%)6.
OCT4/NANOG/DAPI
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Figure 3 | Immunofluorescence analyses demonstrating the expression of characteristic markers at key stages of CLC differentiation. Scale bars, 100 µm.  
See table 1 for a detailed list of the antibodies and concentrations used. The method for staining CLC organoids is described in Procedure Steps 28–39.
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space for the cells to expand and reorganize into organoids with a 
central lumen. Instead, proliferating clumps of cells merge together 
into large aggregates. Single cells or very small clumps may not 
be viable, whereas large clumps gradually migrate and attach to 
the bottom of the plate, forming a monolayer. Consequently, 
the efficiency of this phase depends on careful manipulation of 
the quantity of cells, Matrigel and media. Minor adjustments 
to density and clump size may be required for different hPSC 
lines (see Troubleshooting and Procedure sections, Steps 17–26). 
For resistant lines such as H9, we recommend adding forskolin 
(optional step), which promotes intraluminal fluid secretion and 
facilitates the formation of organoids with a lumen.
Of note, this step starts with a heterogeneous population of cells 
including HBs and CPs, and thus some hepatic contamination is 
expected. However, cells expressing hepatic markers such as AFP 
fail to form organoids and usually gravitate to the bottom of the 
plate. By contrast, by the end of this stage CLC organoids should 
express biliary (CK19, CK7, SOX9; Figs. 3 and 4), but not hepatic 
(AFP), markers and demonstrate functional properties character-
istic of biliary epithelium, such as GGT and alkaline phosphatase 
(ALP) activity (Fig. 5). Importantly, we have noticed differences 
in differentiation efficiency with different batches of Matrigel. For 
resistant hPSC lines, Matrigel should be screened for batches that 
support organoid formation and cholangiocyte functionality.
Controls
Intrahepatic cholangiocytes are not commercially available. 
Therefore, we recommend the use of fresh bile duct tissue 
obtained from liver donors, or frozen isolated common bile duct 
cholangiocytes commercially available (Celprogen) as a positive 
control for the expression of biliary markers.
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Figure 5 | Functional properties of CLC organoids. (a) CLC organoids 
demonstrating characteristic ALP staining. Mouse embryonic feeder cells 
are used as a negative control. Scale bars, 100 µm. (b) GGT activity of CLC 
organoids measured in absorbance units (a.u.); n = 3; mouse embryonic 
feeder cells (MEFs) are used as a negative control. Error bars, s.d.; individual 
data points are demonstrated; *P < 0.05, two-tailed Student’s t-test; F-test 
was used to compare variances, P = 0.1218 (no significant difference in 
variance). GGT and ALP activity were assessed using commercially available 
kits (MaxDiscovery gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit 
and BCIP/NBT Color Development Substrate, respectively) according to the 
manufacturer’s instructions.
MaterIals
REAGENTS
 crItIcal All the reagents listed are reconstituted and stored per the 
manufacturer’s instructions unless specifically stated.
hPSCs (All hPSC lines were derived by the Cambridge Biomedical 
Research Campus (BRC) hIPSC core facility (ethics ref. no. 08/H0311/201 
for Hertfordshire Regional Ethics Committee (REC) and 09/H0304/77 for 
National Research Ethics Service (NRES) Committee East of England,  
Cambridge East)) ! cautIon HPSC derivation should always occur in  
compliance with appropriate national laws and institutional regulations.  
Informed consent must be obtained from human subjects ! cautIon The cell  
lines used in your research should be regularly checked to ensure that they 
are authentic and that they are not infected with mycoplasma.
Gelatin (Sigma, cat. no. G1890)
Water for embryo transfer (Sigma, cat. no. W1503)
Advanced DMEM/F12 (Life Technologies, cat. no. 12634028)
Penicillin–streptomycin (Life Technologies, cat. no. 15140122)
l-Glutamine (Life Technologies, cat. no. 25030024)
β-Mercaptoethanol (Sigma, cat. no. M6250) ! cautIon β-Mercaptoethanol 
is toxic if ingested or inhaled, or following prolonged skin exposure.  
Wear protective clothing and use a fume hood.
FBS (Life Technologies, cat. no. 10500064)  crItIcal Because of  
batch-to-batch variability in serum, serum batches should be screened for 
their capacity to maintain pluripotency for a minimum of two passages.  
Key features of pluripotent cell growth include characteristic colony  
morphology, differentiation potential to all three germ layers and expression 
of pluripotency markers such as NANOG, POU5F1 and SOX2.
Ham’s F-12 Nutrient Mix, GlutaMAX Supplement (Life Technologies,  
cat. no. 31765068)
Iscove’s Modified Dulbecco’s Medium (IMDM; Life Technologies,  
cat. no. 21980065)
Chemically defined lipid concentrate (Life Technologies, cat. no. 11905031)
Monothioglycerol (Sigma, cat. no. M6145)
Transferrin (30 mg/ml; Roche, cat. no. 652202)
Insulin (10 mg/ml; Roche, cat. no. 1376497)
•
•
•
•
•
•
•
•
•
•
•
•
•
Poly(vinyl alcohol) (PVA) 87–90% hydrolyzed (Sigma, cat. no. P8136)
KnockOut Serum Replacement (KOSR; Life Technologies, cat. no. 10828028)
Collagenase IV (Life Technologies, cat. no. 17104019)
Dispase (Invitrogen, cat. no. 17105041)
DMEM/F-12 (Life Technologies, cat. no. 11330032)
RPMI 1640 + GlutaMAX (Gibco, cat. no. 61870)
B-27 supplement containing insulin (Gibco, cat. no. 17504-044)  
 crItIcal Because of batch-to-batch variability in B27, batches should 
be screened for their capacity to support HB and CP differentiation in a 
minimum of two different differentiation experiments. HB and CP  
differentiation should be assessed based on appropriate markers in flow 
cytometry analyses. These include >95% expression of CK19 and AFP for 
HBs and >75% expression of Sox9 and CK19 for CPs (Fig. 4).
MEM nonessential amino acids (MEM-NEAA; Gibco, cat. no. 1140)
Dulbecco’s PBS (DPBS; Life Technologies, cat. no. 14190)
Cell dissociation buffer, enzyme-free, PBS (Gibco, cat. no. 13151014)
William’s E Medium, no phenol red (Invitrogen, cat. no. A12176-01)
Dexamethasone (R&D Systems, cat. no. 1126/100)
DMSO (Sigma, cat. no. D2650)
ITS+ Universal Cell Culture Supplement Premix, 20 ml, 2-liter equivalent 
(Corning, cat. no. 354352)
Nicotinamide (Sigma, cat. no. N0636)
d-Glucose (Invitrogen, cat. no. 15023021)
Sodium bicarbonate powder (Sigma, cat. no. S5761)
2-Phospho-l-ascorbic acid trisodium salt (Sigma, cat. no. 49752)
HEPES solution (Sigma, cat. no. H0887-20ML)
Sodium pyruvate (Invitrogen, cat. no. 11360-070)
Recombinant human activin A (R&D Systems, cat. no. 338-AC)
Recombinant human BMP-4 (R&D Systems, cat. no. 314-BP)
Recombinant human FGF basic, 146 amino acids (R&D Systems,  
cat. no. 233-FB)
LY294002 (Promega, cat. no. V1201)
CHIR99021 (Tocris, cat. no. 4423)
SB431542 (Tocris Bioscience, cat. no. 1614)
Recombinant Human Keratinocyte Growth Factor-2 (FGF10; Source  
Bioscience, cat. no. ABC144)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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Retinoic acid (Sigma, cat. no. R2625)
Y27632 (ROCK inhibitor; Selleck, cat. no. S1049)
Matrigel (BD Biosciences, cat. no. 356237)  crItIcal Because of batch-
to-batch variability in Matrigel, batches should be screened for their capac-
ity to support organoid formation and maturation in a minimum of two 
different differentiation experiments. Organoids should be clearly identified 
following 5 d of culture in Matrigel, although small ring structures can 
be seen as early as 48–72 h. CLC maturation should be assessed based on 
appropriate marker expression in flow cytometry analyses and functional 
assays. These include >75% expression of Sox9 and CK7, and ALP and GGT 
activity (Figs. 3–5).
Recombinant Human EGF Protein (R&D Systems, cat. no. 236-EG)
Cell recovery solution (SLS, cat. no. 354253)
Donkey serum (AbD Serotec, cat. no. c06sb)
Triton-X100 solution (Sigma, cat. no. X100-500ML)
Paraformaldehyde 16% (wt/vol) (PFA; Alfa Aesar, cat. no. 30525-89-4)
GenElute Mammalian Total RNA Miniprep Kit (Sigma, cat. no. RTN-350)
TrypLE Express Enzyme (1×), no phenol red (Gibco, cat. no. 12604021)
Cytokeratin 7 antibody (RCK105; Abcam, cat. no. ab9021; Table 1)
Cytokeratin 7 antibody (Abcam, cat. no. ab68459; Table 1)
Cytokeratin 19 antibody (Abcam, cat. no. ab7754; Table 1)
SOX9 H-90 antibody (Santa Cruz, cat. no. sc-20095; Table 1)
TBX3 (A-20) antibody (Santa Cruz, cat. no. sc-17871; Table 1)
HNF4 (H-171) antibody (Santa Cruz, cat. no. sc-8987; Table 1)
Alpha fetoprotein (AFP) antibody (DAKO, cat. no. A0008; Table 1)
Sox17 antibody (R&D, cat. no. AF1924; Table 1)
TBR2/EOMES antibody (Abcam, cat. no. ab23345; Table 1)
GATA4 (G-4) antibody (Santa Cruz, cat. no. sc-25310; Table 1)
HNF3b/FoxA2 antibody (R&D, cat. no. AF2400; Table 1)
Oct-3/4 (H-134) antibody (Santa Cruz, cat. no. sc-9081; Table 1)
Anti-human NANOG antibody (R&D, cat. no. AF1997; Table 1)
MaxDiscovery gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit 
(Bioo Scientific, 5601-01)
BCIP/NBT Color Development Substrate (Promega, S3771)
Trigene (Distel concentrate; Starlab, cat. no. TM309)
EQUIPMENT
CO2 incubator (Sanyo, cat. no. MCO-18AC) 
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Centrifuge (Eppendorf, cat. no. 5804)
Counting chamber (Superior Marienfeld, cat. no. 0640410)
Disposable serological pipettes, 5, 10 and 25 ml (Corning, cat. nos. 4487, 
4488 and 4489)
Graduated filter tips, 1,000 µl, 200 µl, 20 µl, 10 µl (Starlab,  
cat. nos. S1122-1830, S1120-8810, S1120-1810, S1120-3810)
Centrifuge tubes, 15 ml and 50 ml (Corning, cat. nos. 430791 
 and 430291)
500-ml Vacuum Filter/Storage Bottle System, 0.22-µm pore (Corning,  
cat. no. 431097)
100-mm TC-Treated Culture Dish (Corning, cat. no. 430167)
Costar 12-Well Clear TC-Treated Multiple-Well Plates (Corning, cat. no. 3513)
Costar 24-Well Clear TC-Treated Multiple-Well Plates (Corning, cat. no. 3526)
Plate heater (TAP Biosystem, cat. no. 016-0R10)
Inverted microscope (Olympus, cat. no. CKX41)
REAGENT SETUP
Gelatin for coating tissue culture plates (500 ml) Dissolve 0.5 g of gelatin  
in 500 ml of water for embryo transfer. Heat the mixture at 56 °C until the 
gelatin has fully dissolved (~30 min).  crItIcal Sterilize gelatin solution 
using a vacuum filter/storage bottle system. Store it at room temperature 
(18–25 °C) for up to 1 month.
Serum-containing medium for coating tissue culture plates (500 ml) Add 
50 ml of FBS, 5 ml of glutamine, 5 ml of penicillin–streptomycin (pen/strep) 
and 3.5 µl of β-mercaptoethanol to 450 ml of Advanced DMEM/F12.  
 crItIcal Sterilize serum-containing medium using a vacuum filter/
storage bottle system. Mix the medium well before filtration. Store it at 4 °C 
for up to 1 month.
Chemically defined medium—PVA (CDM–PVA) medium for maintenance 
of hPSCs Combine 0.5 g of PVA, 250 ml of F12 + GlutaMAX, 250 ml of 
IMDM, 5 ml of concentrated lipids, 20 µl of thioglycerol, 350 µl of insulin, 
250 µl of transferrin and 5 ml of pen/strep. Store the solution at 4 °C  
for up to 1 month. Dissolve PVA in IMDM by adding 0.5 g of PVA to 50 ml  
of IMDM and mixing overnight at 4 °C (e.g., using a 50-ml Falcon tube  
on a roller).  crItIcal Sterilize CDM–PVA medium using a vacuum 
filter/storage bottle system. Mix the medium well before filtration.  
Warm it to 37 °C before use.
•
•
•
•
•
•
•
•
•
•
•
taBle 1 | Antibody list.
target  
antigen supplier
catalog 
number
cell  
type analyses
Fluorophore 
type clone Buffer concentration Dilution
SOX17 R&D AF1924 Endoderm IF Unconjugated Polyclonal Donkey  
serum (DS)
200 µg/ml 1:100
GATA4 Santa Cruz sc-25310 FP FC Unconjugated G-4 DS 200 µg/ml 1:100
HNF4A Santa Cruz sc-8987 HB IF Unconjugated H-171 DS 200 µg/ml 1:100
AFP DAKO A-0008 HB IF/FC Unconjugated Polyclonal DS 1.4 g/liter 1:100
TBX3 Santa Cruz sc-17871 HB IF Unconjugated A-20 DS 200 µg/ml 1:100
SOX9 Santa Cruz sc-20095 CP/CLCs IF/FC Unconjugated H-90 DS 200 µg/ml 1:100
CK7 Abcam ab68459 CLC IF/FC Unconjugated EPR1619Y DS 0.111 mg/ml 1:100
CK7 Abcam ab9021 CLC IF/FC Unconjugated RCK105 DS 1 mg/ml 1:100
NANOG R&D AF1997 hPSCs IF/FC Unconjugated Polyclonal DS 200 µg/ml 1:100
Oct3-4 Santa Cruz sc-9081 hPSCs IF/FC Unconjugated H-134 DS 200 µg/ml 1:100
CK19 Abcam ab7754 CLC IF/FC Unconjugated A53-B/A2 DS 1 mg/ml 1:100
TBR2/EOMES Abcam ab23345 DE IF/FC Unconjugated Polyclonal DS 200 µg/ml 1:100
FOXA2 R&D AF2400 FP FC Unconjugated Polyclonal DS 200 µg/ml 1:100
FC, flow cytometry; IF, immunofluorescence.
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Collagenase, 500 ml Dissolve 500 mg of collagenase IV in 400 ml of  
Advanced DMEM/F12 combined with 100 ml of KOSR, 5 ml of l-glutamine 
and 3.5 µl of β-mercaptoethanol.  crItIcal Sterilize collagenase using a 
vacuum filter/storage bottle system. Mix it well before filtration. Store  
collagenase at 4 °C for up to 1 month. Warm it to 37 °C before use.
Dispase, 500 ml Dissolve 500 mg of Dispase in 500 ml of DMEM/F-12.  
 crItIcal Sterilize dispase using a vacuum filter/storage bottle system.  
Mix it well before filtration. Store the solution at 4 °C for up to 1 month. 
Warm it to 37 °C before use.
1:1 Collagenase/dispase solution for dissociation of hPSCs Warm  
collagenase and dispase to 37 °C. Mix 1 volume of collagenase with 1 volume 
of dispase immediately before use. The volumes used are dependent on  
the number and type of plates used. For each 10-cm plate, mix 3 ml of  
collagenase with 3 ml of dispase.
RPMI/B-27 differentiation medium for the differentiation of FP, HBs and 
CPs (500 ml)  Add 10 ml of B-27, 5 ml of NEAA and 5 ml of pen/strep  
to 500 ml of RPMI-1640.  crItIcal We have noticed variation between  
different batches of B-27. B-27 batches should be screened for the capacity  
to support FP, HB and CP differentiation. Appropriate markers for the  
efficiency of each stage are provided in the Experimental design section.  
Store the medium at 4 °C for a maximum of 3 weeks. Warm it to 37 °C  
before use.
Nicotinamide 0.4 M stock solution Dissolve 24.4 g of nicotinamide powder 
in 500 ml of embryo transfer water.  crItIcal Sterilize nicotinamide stock 
solution using a vacuum filter/storage bottle system. Mix it well before  
filtration. Store the solution at 4 °C for up to 3 months.
Sodium bicarbonate 1 M stock solution preparation Dissolve 42 g  
of sodium bicarbonate powder in 500 ml of embryo transfer water.  
 crItIcal Sterilize sodium bicarbonate stock solution using a vacuum 
filter/storage bottle system. Mix it well before filtration. Store the solution  
at 4 °C for up to 3 months.
Ascorbic acid trisodium salt 100 mM stock solution preparation Dissolve 
16.1 g of ascorbic acid trisodium salt powder in 500 ml of embryo transfer 
water.  crItIcal Sterilize ascorbic acid trisodium salt stock solution using 
a vacuum filter/storage bottle system. Mix the solution well before filtration. 
Store it at 4 °C for up to 3 months. Protect it from light.
d-Glucose 1 M stock solution preparation Dissolve 90.1 g of d-glucose 
powder in 500 ml of embryo transfer water. Warm the mixture to 50 °C to 
facilitate dissolution.  crItIcal Sterilize d-glucose stock solution using a 
vacuum filter/storage bottle system. Mix the solution well before filtration. 
Store it at 4 °C for up to 3 months.
Dexamethasone 10 mM stock solution Dissolve 100 mg of dexamethasone 
in 25.4797 ml of DMSO. Prepare 50- to 100-µl aliquots. Store them at −80 °C 
for up to 12 months.
Supplemented William’s E medium for the maturation of CPs to CLCs  
in 3D culture Combine 443 ml of William’s E (WE) medium with 12.5 ml  
of nicotinamide stock solution, 8.5 ml of sodium bicarbonate stock solution, 
1 ml of ascorbic acid trisodium salt stock solution, 7 ml of glucose stock  
solution, 3.15 ml of sodium pyruvate, 10 ml of HEPES solution, 5 ml of  
ITS+ premix, 5 µl of dexamethasone (R&D Systems), 5.3 ml of glutamine  
and 5 ml of pen/strep.  crItIcal Sterilize supplemented WE medium  
using a vacuum filter/storage bottle system. Mix the medium well  
before filtration. Store it at 4 °C for up to 1 month. Warm it to 37 °C  
before use.
Matrigel preparation 10-ml Matrigel vials should be thawed slowly in a 
refrigerator placed at 4 °C overnight. Thawed Matrigel should be mixed well 
and then divided into 1-ml aliquots. Aliquotting of Matrigel should always be 
performed in a tissue culture hood to avoid bacterial contamination. Matrigel 
should be kept constantly on ice to avoid solidification. All equipment  
coming into contact with Matrigel should be precooled to 4 °C. This includes 
pipette tips and media for diluting Matrigel. Tubes for aliquotting should be 
kept on ice. Store Matrigel aliquots at −20 °C or −80 °C for up to 3 months. 
 crItIcal Each aliquot should undergo a maximum of two freeze–thaw 
cycles. This can be achieved by adjusting aliquot volumes accordingly.
50% (vol/vol) Matrigel solution preparation Add 1 volume of  
supplemented WE medium to 1 volume of Matrigel and mix thoroughly.  
To calculate the volume of supplemented WE medium and Matrigel that 
need to be mixed, please use the following formula: 
Volumeof suppleme edWE number of platewells lnt = ×[( - ) ]/24 50 2  
The number of wells is multiplied by 50 µl, which corresponds to the volume 
of each dome (see Step 24) and is divided by 2 to reflect the Matrigel–media 
ratio (50% or 1:1).  crItIcal The supplemented WE medium should be 
precooled to 4 °C.  crItIcal Both Matrigel and the supplemented WE 
medium should be kept on ice during and after the preparation of the  
50% (vol/vol) solution to avoid solidification.
EQUIPMENT SETUP
Gelatin/serum-coated tissue culture plates Add enough gelatin solution  
to fully cover the surface of the plate. Indicative volumes are 6 ml for a 10-cm 
plate and 1 ml for each well of a 12-well plate. Coat for a minimum  
of 30 min at room temperature, and then aspirate the gelatin and replace  
it with enough volume of serum-containing medium to fully cover the  
surface of the plate. Indicative volumes are 6 ml for a 10-cm plate and  
1 ml for each well of a 12-well plate. Store plate in an incubator at 37 °C  
for up to 1 week.  crItIcal Allow a minimum of 24 h at 37 °C before  
using the plate.
Plate heater setup Clean the plate heater with trigene and 70% (vol/vol) 
ethanol and place it in a tissue culture hood. Set the temperature to 37 °C  
and place a 24-well plate on the heating surface.  crItIcal Allow a  
minimum of 30 min for the plate to warm up, before plating Matrigel  
with cells. If you are using multiple plates, these can be prewarmed in an  
incubator for a minimum of 30 min, with each plate placed on the plate 
heater immediately before plating.
proceDure
passaging of hpscs ● tIMInG 1 d
1| Ensure that hPSC colonies are growing and maintaining their characteristic morphology21. We recommend using lines 
that have been stable in culture for at least ten passages. Change the medium daily using CDM–PVA supplemented with 
activin (10 ng/ml) and FGF (12 ng/ml). Proceed to the next step when the cells are 70–80% confluent.
2| Aspirate the medium and wash the plate with Ca2+/Mg2+-free PBS. The volume of PBS depends on the type of plate 
used. Indicative minimum volumes are 6 ml for a 10-cm plate, 1–2 ml for a well of a six-well plate and 0.5 ml for a well  
of a 12-well plate.
3| Aspirate the PBS and add the appropriate volume of 1:1 collagenase/dispase solution. Refer to Step 2 for indicative 
volumes. Incubate at 37 °C for 30–60 min until the majority of the colonies (>90%) have detached.
4| Tilt the plate and wait for the colonies to gravitate to its lowest part, forming a loose pellet. Using a 1,000-µl pipette 
to harvest the cells and transfer them to a 15-ml tube containing 6 ml of CDM–PVA.
©
20
17
 
M
ac
m
ill
an
 P
ub
lis
he
rs
 L
im
ite
d,
 
pa
rt
 
o
f S
pr
in
ge
r 
N
a
tu
re
.
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
protocol
nature protocols | VOL.12 NO.4 | 2017 | 821
5| Allow 1–2 min for the colonies to settle to a loose pellet. Aspirate the supernatant and add 6 ml of CDM–PVA.  
Repeat this step twice for a total of three washes with CDM–PVA.
6| Aspirate the supernatant and resuspend the pellet in 1 ml of CDM–PVA supplemented with activin (10 ng/ml)  
and bFGF (12 ng/ml).
 crItIcal step Using a 1,000-µl pipette, gently break the colonies into small clumps. Clump size can affect differentiation 
efficiency. Aim for clumps of 50–100 cells (Fig. 1b).
7| Prepare new plates by washing gelatin-coated plate with PBS, as described in Step 2. Aspirate the PBS and add the  
appropriate volume of CDM–PVA supplemented with activin (10 ng/ml) and bFGF (12 ng/ml), as described in Step 2.
8| Add 100 µl of the cell suspension (from Step 6) to each 10-cm dish.
 crItIcal step hPSCs should be plated at a density that will allow them to reach 80% confluence in 6–8 d for maintenance 
plates and 3–6 d for differentiation (Fig. 1b). This is usually achieved by using a 1:6–1:10 split ratio. Adjust the volume of 
cell suspension added to each plate based on your split ratio. Optimal split ratios vary and need to be adjusted for each  
individual hPSC line depending on its growth parameters. A typical plating density for our lines is 200,000 cells per 10-cm 
plate for maintenance and 500,000–1,000,000 cells for differentiation.
9| Incubate the cells at 37 °C overnight.
Differentiation of hpscs into De ● tIMInG 3 d
10| Day 1. Ensure that hPSCs have fully attached after plating. Aspirate the medium and add freshly prepared CDM–PVA 
supplemented with activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10 µM) and CHIR99021 (3 µM). 
Incubate the cells at 37 °C overnight.
? trouBlesHootInG
11| Day 2. Replace the medium with freshly prepared CDM–PVA supplemented with activin A (100 ng/ml), bFGF (80 ng/ml), 
BMP-4 (10 ng/ml) and LY294002 (10 µM). Incubate the cells at 37 °C overnight.
12| Day 3. Replace the medium with freshly prepared RPMI/B27 medium supplemented with activin A (100 ng/ml) and  
bFGF (80 ng/ml). Incubate the cells at 37 °C overnight. The typical morphology of the cells at the end of this stage is dem-
onstrated in Figure 1b. A proportion of the cells can be further characterized with flow cytometry and immunofluorescence 
(IF) for the expression of endoderm markers such as Sox17, anticipating >90% positive cells (Figs. 3 and 4).
? trouBlesHootInG
Differentiation of De into Fp cells ● tIMInG 5 d
13| Day 4–6. Replace the medium daily with freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml).
14| Day 7. Assess the homogeneity and morphology of the cells. The typical morphology of the cells on day 7 is shown  
in Figure 1b. If the cells exhibit optimal morphology with minimal contamination from undifferentiated or partially  
differentiated cells, then complete FP differentiation without splitting the cells (option A). For populations with  
suboptimal morphological characteristics and substantial contamination with poorly differentiated cells, or if the cells  
are overgrown, proceed to split the cells (option B).
(a) completion of Fp differentiation without splitting ● tIMInG 2 d
 (i)  Day 7 and 8. Replace the medium daily with freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml). 
? trouBlesHootInG
(B) splitting of cells and completion of Fp differentiation ● tIMInG 2 d
 (i)  Day 7. Prepare new plates as described in Step 7.
 (ii)  Wash the cells once with PBS, as described in Step 2. Add the appropriate volume of cell dissociation buffer as described 
in Step 2 and incubate at 37 °C for 20 min until the cells have detached. Tap the plate to facilitate detachment.
 (iii)  Transfer the cells to a 15-ml tube. Gently aspirate and resuspend the cell solution using a 5-ml serological pipette,  
to facilitate dissociation to single cells.
 (iv)  Wash the plate that contained the cells with 1 volume of RPMI/B27 medium, and transfer the wash to the 15-ml tube.
 (v)  Centrifuge at 444g for 3 min at room temperature. Aspirate the supernatant and resuspend the cells in 6 ml of  
RPMI/B27 medium.
 (vi)  Use a counting chamber to count the number of cells in the suspension.
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 (vii)  Centrifuge the mixture at 444g for 3 min at room temperature. Aspirate the supernatant and resuspend the cells  
in an appropriate volume of freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml) and  
Rho kinase inhibitor Y-27632 (10 µm) for a final concentration of 1 × 106 cells/ml. 
 crItIcal step Y-27632 should always be freshly added and kept in the culture for a minimum of 24 h to improve 
cell survival.
 (viii)  Add the appropriate volume of cell suspension to the new plates to provide a coverage of 150,000 cells/cm2. Ensure 
that this is more than the minimum volume indicated in Step 2, and supplement with freshly prepared RPMI/B27  
medium supplemented with activin A (50 ng/ml) if required.
 (ix)  Incubate the cells at 37 °C overnight. 
 crItIcal step The density of the cells following the split may affect the efficiency of the later steps of  
differentiation. It is critical to plate the cells at an appropriately high density so that the cells are almost confluent 
(90%) following the split. In some cases, not all the cells attach; therefore, it is critical to look at the plates and,  
if necessary, increase the cell number plated to achieve the right confluence. Very high densities promoting growth  
of cells in overlapping layers also have a negative impact on differentiation efficiency and should be avoided.
 (x)  Day 8. Replace the medium with freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml).  
Incubate the cells at 37 °C overnight. Further characterize a proportion of the cells with IF and flow cytometry  
analyses for the expression of foregut markers such as GATA4 (Figs. 3 and 4), anticipating >90% positive cells. 
 crItIcal step The typical morphology of the cells at the end of this stage can be seen in Figure 1b. 
? trouBlesHootInG
Differentiation of Fp cells into HBs ● tIMInG 4 d
15| Day 9–12. Replace the medium daily with freshly prepared RPMI/B27 medium supplemented with SB-431542 (10 µM) 
and BMP-4 (50 ng/ml). Monitor hepatoblast differentiation through the expression of HNF4A, AFP and TBX3 by IF and flow 
cytometry analyses.
 crItIcal step The typical morphology of the cells is demonstrated in Figure 1b. Optimal hepatoblast differentiation  
is necessary for efficient differentiation of later stages. AFP expression should be observed in >95% of the cells by  
day 12 (Figs. 3 and 4).
? trouBlesHootInG
Differentiation of HBs into cps ● tIMInG 4 d
16| Day 13–16. Replace the medium daily with freshly prepared RPMI/B27 medium supplemented with FGF10 (50 ng/ml), 
activin A (50 ng/ml) and retinoic acid (3 µM). Monitor CP differentiation through the expression of Sox9, which should be 
observed in >75% of the cells by day 16 (Fig. 4).
 crItIcal step The typical morphology of the cells is demonstrated in Figure 1b. Optimal CP differentiation is necessary 
for efficient differentiation of later stages.
? trouBlesHootInG
passaging of cps and transfer to 3D culture conditions ● tIMInG 1–2 h
 crItIcal Before starting this step, ensure that the Matrigel and related equipment are prepared as described in the Rea-
gent Setup and that the plate heater and the required number of plates are prepared as described in the Equipment Setup.
17| Day 17. Wash the cells once with PBS and add the appropriate volume of cell dissociation buffer as described in Step 2. 
Incubate the cells at 37 °C for 20 min.
18| Tap the plate to facilitate detachment. The cells should detach as a monolayer or in large clumps. If no detachment  
can be identified after 20 min, proceed to mechanical dissociation with a pipette using a combination of horizontal,  
perpendicular and circular movements. We used a 1,000-µl pipette for harvesting cells from 1 well of a 12-well plate.
19| Transfer the cells to a 15-ml tube. Gently aspirate and resuspend the cell solution 2–3 times, using a 1,000-µl pipette, 
to facilitate dissociation to small clumps.
 crItIcal step Clump size is critical to the efficiency of the following differentiation step and the formation of organoids. 
Aim for clumps of 10–50 cells. Very small clumps and single cells exhibit poor survival, whereas large clumps gravitate to the 
bottom of the plate and fail to form organoids. Optimization of clump size may be required between different lines.
? trouBlesHootInG
20| Wash the plate that contained the cells with 1 volume of RPMI/B27 medium, and transfer the wash to the 15-ml tube. 
Centrifuge the mixture at 444g for 3 min at room temperature. Aspirate the supernatant and resuspend the cells in 6 ml of 
RPMI/B27 medium.
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21| Centrifuge the mixture at 444g for 3 min at room temperature. Aspirate the supernatant.
22| Resuspend the cells in the appropriate volume of freshly prepared 50% (vol/vol) Matrigel supplemented with EGF  
(20 ng/ml) and the Rho kinase inhibitor Y-27632 (10 µm). Mix thoroughly.
 crItIcal step Cholangiocyte progenitors should be plated at a density that will allow the emerging CLC organoids to 
reach 80% confluence in 10 d. This is usually achieved by using a 1:6–1:10 split ratio (1 well of a 12-well plate split into  
10 wells of a 24-well plate). Optimal split ratios vary and must be adjusted for each individual hPSC line depending on its 
growth parameters and differentiation efficiency. A typical plating density for our lines is 1–2 × 105 cells.
 crItIcal step The 50% (vol/vol) Matrigel cell suspension should be kept on ice at all times to avoid solidification.
23| Mix the 50% (vol/vol) Matrigel cell suspension thoroughly while keeping on ice.
 crItIcal step Ensure that 24-well plates have been placed on a plate heater or an incubator at least 30 min before  
plating, as described in the Equipment Setup section. Plating of the 50% (vol/vol) Matrigel cell suspension should happen 
with the plate on the plate heater.
24| To form a Matrigel dome in one well of a 24-well plate, hold the tip of the 1,000-µl pipette close to the surface of a well 
and start pipetting 50 µl of the 50% (vol/vol) Matrigel cell suspension until a small droplet forms. Lower the pipette tip so 
that the droplet touches the warm plate surface, and gently pipette the remainder of the 50 µl.
 crItIcal step Ensure that the droplet does not touch the walls of the well, which could lead to collapse of the Matrigel dome.
25| Allow 1–2 min for the 50% (vol/vol) Matrigel cell suspension to solidify. This can be assessed by gently tilting the plate. 
Turn the plate upside down and incubate at 37 °C for 30 min.
26| Add enough supplemented WE with EGF (20 ng/ml) and Rho kinase inhibitor Y-27632 (10 µm) to cover the Matrigel 
domes. For 1 well of a 24-well plate, we use 1 ml of medium.
 crItIcal step Y-27632 should always be freshly added and kept in the culture for a minimum of 24 h to improve  
cell survival.
? trouBlesHootInG
Differentiation of cps into clc organoids ● tIMInG 10 d
27| Day 17–26. Replace the medium every 2 d with freshly prepared supplemented WE medium with EGF (20 ng/ml).  
Organoids should start forming following 2–4 d of culture. CLC differentiation can be monitored through the expression of 
CK7, which should be observed in >75% of the cells by day 26 (Fig. 4); positive ALP staining (Fig. 5a); and GGT activity 
(Fig. 5b) of CLC organoids.
 crItIcal step The typical morphology of the cells is demonstrated in Figure 1b and supplementary Figure 1.
? trouBlesHootInG
characterization of clc organoids
28| Follow option A to characterize CLC organoids by IF, or follow option B to extract CLCs from Matrigel for  
further analyses.
(a) Immunofluorescence ● tIMInG 2 d
 crItIcal step A Matrigel dilution of 50% (vol/vol) or less should be used for the generation of CLC organoids for staining 
to allow adequate antibody penetration.
 (i)  Day 1. Aspirate the culture medium.
 (ii)  Add 1 ml of 4% (wt/vol) PFA per well of a 24-well plate and incubate the plate for 20 min at room temperature to fix 
the CLC organoids in Matrigel.
 (iii)  Aspirate the PFA.
 (iv)  Wash twice with PBS (10 min per wash).
 (v)  Permeabilize the organoids and block them for 1 h with a 10% (vol/vol) donkey serum and 0.1% (vol/vol) Triton-X100 
solution in PBS at room temperature.
 (vi)  Stain the organoids overnight at 4 °C with primary antibody diluted in a solution of 1% (vol/vol) donkey serum  
and 0.1% (vol/vol) TritonX-100 in PBS.
 (vii)  Day 2. Wash the organoids three times with PBS (45 min per wash).
 (viii)  Stain the CLC organoids for 1 h at room temperature with secondary antibody raised in donkey and diluted  
1:1,000 (vol/vol) in a solution of 1% (vol/vol) donkey serum and 0.1% (vol/vol) TritonX-100 in PBS.
 (ix)  Aspirate the secondary antibody.
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 (x)  Add a solution of Hoechst 33258 1:10,000 (vol/vol) in PBS for 10 min at room temperature.
 (xi)  Wash the organoids three times with PBS (45 min per wash).
 (xii)  Image using a confocal microscope. All IF images (Figs. 2 and 3) were acquired using a Zeiss LSM 700 confocal  
microscope. Imagej 1.48k software (Wayne Rasband, NIHR, USA, http://imagej.nih.gov/ij) was used for image  
processing such as merging of different channels. 
? trouBlesHootInG
(B) extraction of clcs from Matrigel for further analyses ● tIMInG 40 min
 (i)  Aspirate the medium.
 (ii)  Add 500µl per well of a 24-well plate cell recovery solution.
 (iii)  Mechanically dissociate the Matrigel and CLC organoids by scraping with the tip of a P1000 pipette and transfer the 
mixture to a 15-ml Falcon tube.
 (iv)  Incubate the resulting suspension of fragments of Matrigel/CLC organoids in cell recovery solution for 30 min at 4 °C.
 (v)  Centrifuge at 444g, for 4 min at room temperature.
 (vi)  Aspirate the supernatant.
 (vii)  Wash the organoids twice with supplemented WE medium.
 (viii)  Harvest and lyse CLC organoids for RNA extraction using any commercially available kit (we used the GenElute  
Mammalian Total RNA Miniprep Kit) or dissociate into single cells for flow cytometry following incubation with  
TrypLE for 5 min at 37 °C.
? trouBlesHootInG
Troubleshooting advice can be found in table 2.
taBle 2 | Troubleshooting table.
step problem possible reason solution
10 Poor attachment  
of hPSCs
Longer attachment time is  
required
Repeat Step 9, incubating the cells for 1 more day  
before proceeding to Step 10
Colony size is too small Break colonies into slightly bigger clumps that  
gravitate to the bottom of the plate more easily,  
facilitating attachment
Variability between hPSC lines Add the Rho kinase inhibitor Y-27632 to the medium  
during passaging
Poor FBS batch If this problem occurs with more than one line, change  
the FBS batch. Screening of FBS batches may be required  
as outlined in the Reagents section
12 Poor endoderm differ-
entiation efficiency
Suboptimal plating of hPSCs for  
differentiation
Decrease clump size and increase plating density
Variability between lines with  
different sensitivity to activin or  
Wnt signaling
For particularly resistant lines, optimize the dose of activin 
A in Steps 10–12 and that of CHIR in Step 10, by monitoring 
the impact of increased doses on the efficiency of endoderm 
differentiation
14A(i), 
14B(x)
Poor FP differentia-
tion efficiency
Variability between lines For persistent contamination with poorly differentiated cells, 
split the cells as described in Step 14B
Suboptimal plating of cells  
following split in Step 14B
For poor differentiation efficiency following a split,  
optimize cell density, ensuring that the cells are  
confluent by the following day
Reduced activity of growth factors Check activin-A activity
Use growth factors that have undergone <5 freeze–thaw cycles
Poor B27 batch For particularly resistant lines, change B27 batch.  
Screening of B27 batches may be required as outlined in  
the Reagents section
(continued)
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taBle 2 | Troubleshooting table (continued).
step problem possible reason solution
14B(x) Poor attachment  
after the split
Suboptimal plating of cells after  
the split in Step 14B
Increase the cell density
Use a viability dye such as trypan blue when counting  
the cells to ensure that the appropriate number of live cells  
is plated
Poor FBS batch If this problem occurs with more than one line, change FBS 
batch. Screening of FBS batches may be required as outlined 
in the Reagents section
15 Poor hepatoblast  
differentiation
Suboptimal performance of  
previous steps
Check and optimize the efficiency of differentiation to foregut 
progenitors
Increase the plating density in Step 14B to ensure that the 
cells are confluent by Step 15
Reduced activity of growth factors Check SB431542 activity
Use growth factors that have undergone <5 freeze–thaw cycles
Variability between lines with differ-
ent sensitivities to activin signaling
For particularly resistant lines, the dose of SB431542  
can be increased
Poor B27 batch For particularly resistant lines, change the B27 batch.  
Screening of B27 batches may be required as outlined in  
the Reagents section
16 Poor cholangiocyte 
progenitor differen-
tiation
Variability between lines with 
increased sensitivity to the previous 
differentiation stage, resulting  
in hepatic commitment of the  
generated hepatoblasts
Minimize hepatoblast contamination by optimizing the  
duration of the previous stage to avoid hepatic commitment 
by the cells. Aim for the minimum duration that allows  
upregulation of hepatoblast markers
Reduced activity of growth factors Check activin A and retinoic acid activity
Increase the dose of activin A
Use growth factors that have undergone <5 freeze–thaw cycles
Variability between lines The differentiation efficiency of hPSC-derived hepatoblasts 
into cholangiocyte progenitors is dependent on the culture 
media. Optimization may be required for particularly  
resistant lines. Advanced DMEM/F12 can replace RPMI/B27  
for selected lines
Poor B27 batch For particularly resistant lines, change the B27 batch. 
Screening of B27 batches may be required as outlined in the 
Reagents section
19 Clump size is too 
small/single cells 
are found following 
incubation with cell 
dissociation buffer
Variability between lines Reduce the cell dissociation buffer incubation time
For sensitive lines, omit Step 18 (incubation with cell  
dissociation buffer) and proceed to mechanical dissociation 
only in Step 19
If even mechanical dissociation alone results in single cells/
small clumps check the cell density and plate the cells at a 
higher density in Step 14B
(continued)
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● tIMInG
Steps 1–9, passaging of hPSCs: 1 d
Steps 10–12, differentiation of hPSCs into DE: 3 d
Steps 13 and 14, differentiation of DE into FP cells: 5 d
Step 15, differentiation of FP cells into HBs: 4 d
Step 16, differentiation of HBs into CPs: 4 d
Steps 17–26, passaging of CPs and transfer to 3D culture conditions: 1–2 h
Step 27, differentiation of CPs into CLC organoids: 10 d
Step 28A, IF staining of CLC organoids: 2 d
Step 28B, extraction of cells from Matrigel for further analyses: 40 min
antIcIpateD results
We describe a methodology for the differentiation of hPSCs into functional CLC organoids in 26 d. The early stages of our 
protocol (DE, FP, HB) result in >90% cells expressing endoderm and then FP markers (Fig. 4). However, biliary specification 
of HBs results in 75% CK19+/SOX9+ CPs, which mature into a population of 75% CK7+ CLCs during the final step of our  
differentiation (Fig. 4). The resulting CLC organoids should express biliary markers such as CK19 and CK7 in IF analyses  
taBle 2 | Troubleshooting table (continued).
step problem possible reason solution
26 Poor cell survival  
following transfer  
to 3D culture
Variability between lines Optimize the clump size. More sensitive lines may require 
larger clump sizes
Optimize the plating density. Low plating densities are  
associated with poor survival
Reduced activity of reagents Check Y-27632 activity and ensure that Y-27632 is freshly  
prepared
Increased cell death secondary to 
vigorous mechanical dissociation
Avoid vigorous mechanical dissociation of the cells during  
passaging
27 Poor organoid forma-
tion and/or poor CLC 
differentiation and/or 
poor CLC function
Suboptimal performance of  
previous steps
Check the differentiation efficiency of cholangiocyte  
progenitors
Variability between lines Optimize the clump size and plating density. Aim for smaller 
clumps and lower density if there is substantial attachment of 
cells to the bottom of the plate
For resistant lines, consider adding forskolin to the  
culture medium
Poor Matrigel batch For particularly resistant lines, change the Matrigel batch. 
Screening of Matrigel batches may be required as outlined in 
the Reagents section
28A(xii) Unsuccessful staining Poor antibody penetration Decrease the Matrigel dilution to 40%
Place the plate on a laboratory rocker during the staining and 
washing steps
Difficulties acquiring optimal  
images in 3D while CLC organoids  
are embedded in Matrigel
Grow CLC organoids on chamber slides and use an  
alternative staining method; remove chambers and  
snap-freeze or repeat Steps 27–37 and use a coverslip  
to flatten organoids
Inadequate optimization for  
antibodies
Optimize antibody concentration and duration of washing and 
staining steps
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(Figs. 2 and 3). Hepatic markers (AFP, albumin) can still be detected in these stages because of the presence of a  
contaminating population of hepatic-lineage cells, but these should be identified only in clumps of cells without a lumen  
or attached to the bottom of the plate. Furthermore, CLC organoids can be validated further for additional cholangiocyte 
markers such as CFTR, AE2 and secretin receptor6, and they should demonstrate functional properties such as luminal  
accumulation of rhodamine-123, and GGT and ALP activity (Fig. 5). The methods used to characterize CLC organoids  
(flow cytometry, IF, rhodamine-123 accumulation, GGT activity and ALP staining) have been described elsewhere6.
Our platform promotes substantial cell expansion. Using three different hPSC lines, we observed an average yield  
of >50 × 106 CLCs per 1 × 106 hPSCs. Proliferation should be particularly evident during the generation of CLC organoids.  
1 × 105 CPs should give rise to 50–100 CLC organoids with diameters ranging between 100 and 1,000 µm. However,  
variations in terms of the expansion potential and the differentiation efficiency of our protocol can occur. This can be  
attributed to inherent differences between hPSC lines and batch-to-batch variability for some of the reagents, including 
Matrigel. For reproducible results, the use of fresh medium and well-preserved, small-molecule, recombinant protein and 
Matrigel stocks is essential.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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